| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.11▲ | 8.09▲ | 8.04▲ | 7.81▲ | 7.07▲ |
| MA10 | 8.13▲ | 8.01▲ | 7.98▲ | 7.30▲ | 7.51▲ |
| MA20 | 8.12▲ | 7.96▲ | 8.00▲ | 7.25▲ | 7.13▲ |
| MA50 | 8.01▲ | 7.89▲ | 7.46▲ | 7.64▲ | 7.27▲ |
| MA100 | 7.96▲ | 7.41▲ | 7.19▲ | 7.14▲ | 5.88▲ |
| MA200 | 8.00▲ | 7.17▲ | 7.20▲ | 7.23▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | 0.020▲ | -0.012▼ | 0.155▲ | 0.010▲ |
| RSI | 60.992▲ | 62.661▲ | 64.289▲ | 60.817▲ | 59.127▲ |
| STOCH | 27.759 | 81.920▲ | 78.617 | 77.099 | 28.211 |
| WILL %R | -38.235 | -11.607▲ | -11.207▲ | -15.525▲ | -36.426 |
| CCI | 28.213 | 125.109▲ | 179.537▲ | 127.364▲ | 51.766 |
| ▲ MA | $EPRX MA(20) Crossed Above MA(200) | Set Alert |
|
Wednesday, November 11, 2026 02:09 PM
Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.
|
|
Wednesday, November 11, 2026 02:09 PM
Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.
|
|
Tuesday, November 10, 2026 05:02 AM
Reached target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis (EoE) Phase 2b interim analysis ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/11/26 | 7.81 | 8.23 | 7.61 | 8.15 | 774,436 |
| 12/11/26 | 7.94 | 8.06 | 7.62 | 7.81 | 398,538 |
| 11/11/26 | 7.95 | 8.49 | 7.95 | 8.06 | 615,849 |
| 10/11/26 | 7.33 | 7.67 | 7.20 | 7.63 | 475,800 |
| 09/11/26 | 7.23 | 7.65 | 6.94 | 7.42 | 566,777 |
| 06/11/26 | 6.60 | 6.89 | 6.52 | 6.89 | 583,894 |
| 05/11/26 | 6.77 | 6.87 | 6.30 | 6.60 | 787,812 |
| 04/11/26 | 7.04 | 7.04 | 6.60 | 6.76 | 659,523 |
| 03/11/26 | 6.83 | 7.07 | 6.74 | 6.88 | 456,394 |
| 02/11/26 | 6.92 | 6.96 | 6.64 | 6.76 | 344,294 |
|
|
||||
|
|
||||
|
|